Cibus, Inc. (NASDAQ: CBUS) is a Healthcare company (Biotechnology) with a market capitalization of $106M. The Maz Rating grades it against the other companies in its sector.
Cibus, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.39, Cibus, Inc. trades at 22.7x sales. Over the last twelve months it generated about $5M of revenue and a net loss of $118M. It runs a gross margin of 47.9%, an operating margin of -1125.6% and a net margin of -2131.4%. It shows return on equity of -581.5%, return on invested capital of -17.5% and a free cash flow yield of -41.8%. On the balance sheet: a debt-to-equity ratio of -5.62 and a current ratio of 0.95. Over the past 52 weeks the share price ranged from $1.02 to $4.19, with a beta of 1.57.
Cibus, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 3 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Cibus, Inc. (CBUS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.48% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.86% / 30% · Interest income / Revenue 5.50% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.48% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.86% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 5.50% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.48% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.86% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 5.50% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 39.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 5.74% / 33.33% · Receivables / Avg Assets (4Q) 0.27% / 33.33% · Interest income / Revenue 5.50% / 5% | Fail |
| FTSE | Debt / Total Assets 0.19% / 33.33% · (Cash+ST Inv) / Total Assets 3.55% / 33.33% · (Cash+Recv) / Total Assets 3.55% / 33.33% · Interest income / Revenue 5.50% / 5% | Fail |
No. As of September 2026, Cibus, Inc. (CBUS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Cibus, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 5.50% of each dividend: Cibus, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.